INGELHEIM, Germany--(BUSINESS WIRE)--The first patient with atrial fibrillation (AF) has been enrolled in the global RE-CIRCUIT™ study.4 The study assesses the safety and efficacy of uninterrupted anticoagulation with dabigatran etexilate (Pradaxa®) during ablation procedures compared to warfarin.1 Results from the RE-CIRCUIT™ study are expected during 2016.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
